东诚药业：氟[18F]思睿肽注射液预计2026年上半年提交NDA

Core Viewpoint - The company is making steady progress on its key products before the IPO, with specific timelines for NDA submissions for its investigational drugs [2] Group 1: Product Development Progress - The impurity supplement study for 18F-APN-1607 is ongoing, with no specific completion date mentioned [2] - The NDA for fluorine-18 labeled somatostatin analog (氟[18F]思睿肽) is expected to be submitted in the first half of 2026, while the NDA for fluorine-18 labeled alpha peptide (氟[18F]阿法肽) is anticipated in 2027 [2] - The pre-NDA communication for 99mTc-GSA is in progress, although specific details were not provided [2] Group 2: Market Strategy - The company is committed to actively promoting the research and development progress to expedite the market launch of its products [2]